The ECHDC3 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Jurkat T-lymphocyte cells, featuring targeted disruption of the ECHDC3 gene. This loss-of-function model serves as a valuable tool for investigating mitochondrial fatty acid metabolism within a leukemia background. The polyclonal nature of the knockout pool preserves cellular heterogeneity, allowing researchers to study population-level metabolic effects without the clonal artifacts often associated with single-cell-derived lines, thus better reflecting physiological variability in gene disruption responses.
Jurkat cells are a widely utilized human T-cell leukemia line that recapitulates many aspects of T-cell signaling, activation, and apoptosis. They have been instrumental in elucidating T-cell receptor pathways and serve as a standard model for immune cell biology and cancer research. Jurkat cells exhibit robust proliferation and defined metabolic profiles, making them particularly suitable for exploring the intersection between immune function and cellular metabolism. Their genetic tractability and established use in functional genomics further support targeted gene perturbation studies aimed at dissecting metabolic regulatory networks in malignant T cells.
ECHDC3 encodes enoyl-CoA hydratase domain-containing protein 3, which catalyzes the second step of mitochondrial fatty acid ??-oxidation: the hydration of trans-2-enoyl-CoA to 3-hydroxyacyl-CoA. This reaction is essential for the sequential breakdown of fatty acids, ultimately yielding acetyl-CoA, NADH, and FADH2 for ATP generation. ECHDC3 expression is regulated by the transcription factors PPAR?? and PGC-1??, and its activity is modulated by AMPK signaling, linking nutrient sensing to fatty acid catabolism. Within the ??-oxidation pathway, ECHDC3 interacts with acyl-CoA dehydrogenases, 3-hydroxyacyl-CoA dehydrogenase, and thiolase, forming a coordinated enzyme system that drives mitochondrial energy production from lipid substrates.
In the Jurkat T-cell context, disruption of ECHDC3 is predicted to impair mitochondrial fatty acid oxidation, leading to reduced acetyl-CoA and NADH pools and compromised ATP synthesis. This metabolic defect can hinder the energy-intensive processes of T-cell activation and proliferation, exposing potential metabolic vulnerabilities in leukemic cells. The model thus enables detailed examination of how fatty acid utilization supports the bioenergetic and biosynthetic demands of malignant T lymphocytes, providing insights into metabolic reprogramming in cancer and the role of mitochondrial function in immune cell fate decisions.
Researchers can employ this model to explore fatty acid oxidation in T-cell activation using Seahorse metabolic flux analysis to measure oxygen consumption rates, fatty acid oxidation assays with labeled palmitate to trace lipid catabolism, and RT-qPCR or Western blot to quantify changes in ??-oxidation enzymes. Additional applications include assessing mitochondrial membrane potential with JC-1 staining, visualizing neutral lipid accumulation via LipidTOX, and screening for metabolic drug targets in leukemia. This knockout tool is well-suited for mechanistic studies of metabolic syndrome?Crelated pathways and hepatocellular carcinoma metabolic adaptations. For further information or to discuss custom applications, please contact Ascent Research.
